You Won’t Believe Who Just Cheered Iran’s Islamic Revolution
OpenAI Fires Executive Who Warned About 'Adult Mode'
Axios Is Having a Tough Go of Things This Week, and Media Are...
In Defense of Female Inmates
Canada's MAiD Program Is About to Get Even More Horrifying
Backlash Grows Over the University of Notre Dame's Appointment of Pro-Abortion Professor
Megyn Kelly’s Moral Blind Spot: Refusing to Condemn Candace Owens
Democrat Ohio Senate Hopeful Sherrod Brown Supports an AG Candidate Who Vowed to...
California Campaign Adviser Sentenced to 48 Months in PRC Agent Case
19 New York City Residents Reportedly Freeze to Death After Mamdani Changes Homeless...
Colorado Woman Allegedly Billed $400K to Medicaid for Family’s Phantom Medical Rides
Philadelphia Men Allegedly Used ChatGPT to Scam Minnesota Out of $3.5M
Queens Duo Charged in Alleged Decade-Long $120 Million Medicare Scam
White House Blasts Washington Post Over ‘Breaking’ Story Trump Announced Last Year
‘Customer Has Spoken’: Ford Motor Company Faces $11 Billion Hit on EV Investments
Tipsheet

FDA Authorizes COVID-19 Booster for Ages 5 to 11

AP Photo/Ted Jackson

On Tuesday, the U.S. Food and Drug Administration (FDA) authorized a booster dose of the Pfizer-BioNTech COVID-19 vaccine for children ages 5 to 11. 

The FDA published a news release on Tuesday explaining how the single-use booster can be administered to children in this age group at least five months after their primary two-dose vaccine.

Advertisement

“Since authorizing the vaccine for children down to 5 years of age in October 2021, emerging data suggest that vaccine effectiveness against COVID-19 wanes after the second dose of the vaccine in all authorized populations. The FDA has determined that the known and potential benefits of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age at least five months after completing a primary series outweigh its known and potential risks and that a booster dose can help provide continued protection against COVID-19 in this and older age groups,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, in the release.

Townhall covered in December that the FDA authorized the Pfizer booster for 16 and 17 year olds as the Delta variant spread and the Omicron variant emerged. In early January, the FDA authorized a booster shot for children 12 through 15 years of age.

The release noted that the booster dose for 5 to 11 year olds was assessed in about 400 children five to nine months after they received their primary vaccine dosage. The most common side effects were pain, redness, swelling, fatigue, headache, muscle and joint pains, chills and fever. 

Advertisement

Related:

COVID-19 PFIZER

This age demographic is the youngest to date to receive authorization from the FDA for a COVID-19 booster shot. In February, Townhall reported how Pfizer and BioNTech were testing a third dose of the vaccine, following “disappointing” results from the two-shot regime in children under 5. Shortly after, Pfizer announced it was delaying the application process for Emergency Use Authorization for their vaccine for children ages 6 months through 4 years.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement